Somewhat Positive Media Coverage Somewhat Unlikely to Impact Viking Therapeutics (VKTX) Stock Price

News coverage about Viking Therapeutics (NASDAQ:VKTX) has trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Viking Therapeutics earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.1172948602115 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Shares of Viking Therapeutics (VKTX) traded up $0.01 during midday trading on Monday, reaching $5.01. The company’s stock had a trading volume of 806,000 shares, compared to its average volume of 1,122,300. The stock has a market capitalization of $146.40 and a price-to-earnings ratio of -5.89. Viking Therapeutics has a 52 week low of $0.88 and a 52 week high of $5.19.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). equities research analysts predict that Viking Therapeutics will post -0.86 EPS for the current fiscal year.

Several analysts have recently commented on VKTX shares. Roth Capital set a $6.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a research report on Wednesday, November 29th. Maxim Group set a $8.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a research report on Tuesday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Viking Therapeutics in a research report on Friday, November 10th. Finally, ValuEngine lowered shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st.

COPYRIGHT VIOLATION NOTICE: This story was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Insider Buying and Selling by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply